id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-D-5601-0016,FDA,FDA-2024-D-5601,E6(R3) Good Clinical Practice: Annex 2; International Council for Harmonisation; Draft Guidance for Industry; Reopening of the Comment Period,Notice,Extension of Comment Period,2025-03-13T04:00:00Z,2025,3,2025-03-13T04:00:00Z,,2025-03-13T13:11:09Z,2025-04026,0,0,09000064869e6d90
FDA-2024-D-5601-0002,FDA,FDA-2024-D-5601,E6(R3) Good Clinical Practice: Annex 2; International Council for Harmonisation - Draft Guidance,Other,Guidance,2024-12-30T05:00:00Z,2024,12,2024-12-30T05:00:00Z,2025-04-01T03:59:59Z,2025-04-01T01:00:37Z,,1,0,09000064868954e6
FDA-2024-D-5601-0001,FDA,FDA-2024-D-5601,E6(R3) Good Clinical Practice: Annex 2; International Council for Harmonisation; Draft Guidance,Notice,Notice of Availability,2024-12-30T05:00:00Z,2024,12,2024-12-30T05:00:00Z,,2024-12-30T16:08:36Z,2024-31275,0,0,0900006486895165